$AMRN - On our watch/trading lists. A Biotech stock that has earnings and seeking further approval of its drug Vascepa. This a moderate risk/high reward stock with very active options.Amarin Q3 Vascepa sales topped consensus, says JefferiesJefferies analyst Michael Yee says Amarin this morning reported Q3 Vascepa sales of $112M, in line with his estimate and ahead of consensus at $110M, while its earnings also beat on lower expenses. Guidance was maintained at $380M-$420M and consensus of $408M is already at the upper half, Yee tells investors in a research note. The analyst continues to believe the FDA will be "logical and rational in its review and make a decision that is best for the public given the significant landmark data and the clear benefit/risk formula that favors Vascepa." He keeps a Buy rating on Amarin with a $30 price target. The stock in premarket trading is up 58c to $18.03. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page